Insider Selling: Alphatec Holdings, Inc. (NASDAQ:ATEC) COO Sells 27,453 Shares of Stock

Alphatec Holdings, Inc. (NASDAQ:ATEC) COO Scott Lish sold 27,453 shares of the business’s stock in a transaction on Thursday, February 6th. The shares were sold at an average price of $11.49, for a total value of $315,434.97. Following the transaction, the chief operating officer now owns 867,677 shares of the company’s stock, valued at approximately $9,969,608.73. The trade was a 3.07 % decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through this hyperlink.

Alphatec Stock Down 0.5 %

Shares of NASDAQ ATEC traded down $0.06 during midday trading on Friday, reaching $11.36. 998,281 shares of the company’s stock traded hands, compared to its average volume of 1,776,835. The company has a market cap of $1.61 billion, a price-to-earnings ratio of -8.88 and a beta of 1.43. The stock’s 50 day simple moving average is $10.26 and its 200-day simple moving average is $8.13. The company has a quick ratio of 1.15, a current ratio of 2.32 and a debt-to-equity ratio of 30.21. Alphatec Holdings, Inc. has a one year low of $4.88 and a one year high of $17.34.

Institutional Trading of Alphatec

Hedge funds and other institutional investors have recently bought and sold shares of the stock. BNP PARIBAS ASSET MANAGEMENT Holding S.A. grew its position in shares of Alphatec by 11.3% in the 3rd quarter. BNP PARIBAS ASSET MANAGEMENT Holding S.A. now owns 2,928,094 shares of the medical technology company’s stock worth $16,280,000 after buying an additional 297,850 shares during the last quarter. Barclays PLC increased its position in shares of Alphatec by 362.3% during the third quarter. Barclays PLC now owns 170,546 shares of the medical technology company’s stock worth $948,000 after purchasing an additional 133,653 shares in the last quarter. Franklin Resources Inc. lifted its holdings in shares of Alphatec by 299.3% during the 3rd quarter. Franklin Resources Inc. now owns 64,450 shares of the medical technology company’s stock valued at $343,000 after purchasing an additional 48,308 shares during the last quarter. AlphaCentric Advisors LLC acquired a new stake in shares of Alphatec in the 3rd quarter worth $2,057,000. Finally, Royce & Associates LP grew its stake in Alphatec by 15.9% during the 3rd quarter. Royce & Associates LP now owns 1,212,286 shares of the medical technology company’s stock worth $6,740,000 after buying an additional 165,954 shares during the last quarter. Institutional investors own 66.35% of the company’s stock.

Analysts Set New Price Targets

ATEC has been the subject of several research analyst reports. HC Wainwright reiterated a “buy” rating and set a $20.00 target price on shares of Alphatec in a research report on Tuesday, January 14th. Needham & Company LLC lifted their price objective on shares of Alphatec from $13.00 to $16.00 and gave the company a “buy” rating in a report on Monday, January 13th. Finally, Barclays upped their target price on shares of Alphatec from $20.00 to $21.00 and gave the stock an “overweight” rating in a research note on Wednesday, January 22nd. One investment analyst has rated the stock with a hold rating and eight have issued a buy rating to the company. According to data from MarketBeat, the stock currently has an average rating of “Moderate Buy” and an average price target of $17.56.

About Alphatec

Alphatec Holdings, Inc, a medical technology company, designs, develops, and advances technologies for the surgical treatment of spinal disorders in the United States and internationally. It manufactures and sells implants and instruments through third-party suppliers. The company offers Alpha InformatiX product platform, including EOS imaging system that provides full-body imaging; VEA alignment mobile application, which leverages EOS technology to more quickly quantify alignment parameters on a mobile device; SafeOp Neural InformatiX System that automates electromyographic and somatosensory evoked potential monitoring; and Valence, an intra-operative system that integrates navigation and robotics into spine procedures, as well as Sigma Prone TransPsoas (PTP) Access and PTP Patient Positioning Systems.